Pharmaceutical intermediates

Elinzanetant Intermediates

9 pharmaceutical intermediates for Elinzanetant. Indication: Hot flashes; breast cancer; vasomotor syndrome; menopausal symptoms.

About Elinzanetant

Originator: GlaxoSmithKline (GSK)
Indication: Hot flashes; breast cancer; vasomotor syndrome; menopausal symptoms
Approved Date: 07/10/2025
NCE Patent: 10/24/2030
DS/DP: 09/15/2026

9 intermediates currently listed for Elinzanetant. Request specifications, documentation or a quotation for any item below.

Elinzanetant intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
N-Boc-O-Benzyl-D-serine	47173-80-8	/	/
6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine hydrochloride	2642577-31-7	/	/
N-[6-Chloro-4-(4-fluoro-2-methylp henyl)-3-pyridinyl]-N,a,a-trimethy	825643-73-0	/	/
3-Morpholinemethanol, 4-(phenylmethyl)-, hydrochloride	916483-67-5	/	/
(7S,9aS)-7-((Benzyloxy)methyl)octahydropyrazino[2,1-c][1,4]oxazine dioxalate salt	1268364-46-0	/	/
2-(3,5-bis(trifluoroMethyl)phenyl)-2-Methyl propanoic acid	289686-70-0	/	/
((7S)-octahydropyrazino[2,1-c][1,4]oxazin-7-yl)methanol	929047-29-0	/	/
4-Boc-3-morpholinecarboxylic Acid	212650-43-6	/	/
2-(3,5-bis-trifluoromethylphenyl)-2-methyl-propionyl chloride	289686-69-7	/	/

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态